Far from the laboratories and boardrooms where it was born, a Chinese-developed antibody has passed a major checkpoint on its way to European patients. Europe's medicines committee has recommended sintilimab, sold there as Zybrivo, for certain adults with advanced lung cancer that carries no EGFR or ALK mutations. Lung cancer remains the deadliest cancer across the Union, so each step toward a new option carries weight beyond the market. The final word now belongs to the European Commission, and until it speaks, the drug stands at the threshold rather than inside the door.
Innovent's Sintilimab Wins EU CHMP Backing, Clearing Path Toward First European Approval
The last mile before a European launch
Why does this opinion matter if it isn't an approval yet?
Because it's the step right before one. The CHMP has recommended it, and the European Commission is expected to decide within months. Approval would cover the EU plus Iceland, Norway and Liechtenstein.
And it would be Innovent's first independently developed drug authorized in Europe?
Yes, that's the milestone the company is pointing to.
Worth noting that's conditional. The Commission hasn't ruled, and the timing is described only as the coming months.
What does the trial actually show?
ORIENT-11 enrolled 397 patients. Median overall survival was 24.2 months versus 16.8, and progression risk fell 52%.
Those figures come from the company's disclosure. I'd also note the restriction: patients without EGFR or ALK aberrations, with non-squamous disease. It isn't a blanket lung cancer approval.
Does anything suggest a safety problem?
The report says no new safety signals, consistent with other PD-1 inhibitors and the chemotherapy used.
Fine, but the source gives no detail on adverse event rates. And whether sales follow is unknown. Reimbursement and distribution in Europe are still to be built, and the report doesn't say how far along that is.
Il Polso
- A positive CHMP opinion has moved Zybrivo to the last stage before a European decision, yet the drug is not approved until the Commission rules.
- The ORIENT-11 trial showed a 52% cut in progression risk and a 35% cut in death risk, giving the recommendation its clinical urgency.
- Median survival rose from 16.8 to 24.2 months, a gap that makes patients and clinicians pay close attention to this decision.
- Innovent is preparing for its first independently won EU authorization, and its success will hinge on building European distribution and reimbursement.
- The Commission's decision, expected within months, will determine whether the opinion becomes a launch covering 30 countries.
Far from the laboratories and boardrooms where it was born, a Chinese-developed antibody has passed a major checkpoint on its way to European patients. Europe's medicines committee has recommended sintilimab, sold there as Zybrivo, for certain adults with advanced lung cancer that carries no EGFR or ALK mutations. Lung cancer remains the deadliest cancer across the Union, so each step toward a new option carries weight beyond the market. The final word now belongs to the European Commission, and until it speaks, the drug stands at the threshold rather than inside the door.
The European Medicines Agency's CHMP has recommended sintilimab, the PD-1 inhibitor made by Innovent Biologics and branded Zybrivo in Europe, as a first-line treatment alongside chemotherapy for adults with advanced non-squamous non-small cell lung cancer. The recommendation covers patients without EGFR or ALK aberrations whose disease is locally advanced beyond curative surgery or chemoradiation, or metastatic. It is an opinion, not yet an approval. The European Commission will decide in the coming months, and if it agrees, the authorization would reach the 27 EU member states plus Iceland, Norway and Liechtenstein. It would be the first drug Innovent developed independently to win European approval.
The case rests on ORIENT-11, a randomized, double-blind, placebo-controlled Phase 3 trial of 397 patients. Progression risk fell by 52%, with median progression-free survival of 8.9 months against 5.0 months. Death risk fell by 35%, with median overall survival of 24.2 months against 16.8 months. The safety profile matched known PD-1 and chemotherapy effects, with no new signals.
Innovent's Chief R&D Officer for Oncology, Zhou Hui, called the opinion an important milestone that brings the drug closer to European patients. The stakes are real: lung cancer is the leading cause of cancer death in the EU, with about 319,000 diagnoses in 2022, and non-small cell lung cancer accounts for most of them. In China, sintilimab is already approved for ten indications and has reached roughly 3 million patients.
For investors, the opinion leaves the drug at the final stage before launch. The Commission's decision is the next checkpoint, and how well Innovent builds distribution and reimbursement across major European markets will determine whether overseas revenue follows.
The European Medicines Agency's human medicines committee, the CHMP, has issued its first positive opinion on sintilimab, the PD-1 inhibitor made by Innovent Biologics (01801.HK) and branded in Europe as Zybrivo. The committee recommends approving it alongside chemotherapy as a first-line treatment for adults with advanced non-squamous non-small cell lung cancer.
The recommended indication is specific. Zybrivo would be given with pemetrexed and platinum-based chemotherapy to adults whose tumors carry no EGFR or ALK genomic aberrations. Their disease must be either locally advanced and not treatable by curative surgery or chemoradiation, or metastatic. The opinion is not yet an approval. The European Commission is expected to make the final decision on marketing authorization in the coming months. If it agrees, the authorization would cover all 27 EU member states plus Iceland, Norway and Liechtenstein. It would also be the first drug Innovent developed independently to win marketing authorization in Europe.
The opinion rests on ORIENT-11, a Phase 3 trial that was randomized, multicenter, double-blind and placebo-controlled. It enrolled 397 adults with locally advanced, metastatic or recurrent non-squamous NSCLC, regardless of PD-L1 expression. Patients were randomized 2:1 to sintilimab or placebo, each combined with pemetrexed and platinum chemotherapy. The primary endpoint was progression-free survival, judged by a blinded independent imaging review committee.
The results favored the sintilimab arm. The risk of disease progression or death fell by 52%, with median progression-free survival of 8.9 months against 5.0 months for placebo plus chemotherapy. The risk of death fell by 35%, and median overall survival reached 24.2 months against 16.8 months. On safety, the profile matched what is known for PD-1 inhibitors and for the chemotherapy drugs used, and no new safety signals were identified.
Zhou Hui, Innovent's Chief R&D Officer for Oncology, called the opinion an important regulatory milestone in the company's international development program, one that brings it closer to European patients. He said ORIENT-11 showed clear clinical benefit, that approval would give European patients with non-squamous NSCLC a new option, and that the company will keep advancing its pipeline.
The disease is common in Europe. Lung cancer is the leading cause of cancer death in the EU, accounting for about one-fifth of such deaths. Roughly 319,000 people in the EU were diagnosed in 2022, and non-small cell lung cancer makes up 85% to 90% of cases. Sintilimab is a fully human IgG4 monoclonal antibody that binds PD-1 and blocks its interaction with the PD-L1 and PD-L2 ligands.
In China the drug is already approved for ten indications: squamous NSCLC, EGFR/ALK wild-type non-squamous NSCLC, non-squamous NSCLC after EGFR tyrosine kinase inhibitor failure, hepatocellular carcinoma, gastric or gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, endometrial cancer, colorectal cancer, renal cell carcinoma and classic Hodgkin lymphoma. Cumulative treatment is about 3 million patients.
Innovent was founded in 2011 and has 20 marketed products, one under review by China's National Medical Products Administration, six in Phase 3 or pivotal trials and 20 early-stage clinical candidates. It reports more than 30 strategic collaborations, with partners including Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte and MD Anderson Cancer Center, with a combined value above CNY 350 billion (about $52.5 billion).
For investors, the opinion is not final approval but leaves the drug at the last stage before a European launch. The Commission's decision is the next checkpoint. After that, how quickly Innovent builds distribution and reimbursement capability in major European markets will shape whether overseas revenue materializes.
Citazioni salienti
The CHMP's positive opinion is an important regulatory milestone in Innovent's international development program and brings it closer to European patients.— Zhou Hui, Chief R&D Officer for Oncology, Innovent